UBS Group
ACUR

UBS Group’s Acura Pharmaceuticals ACUR Stock Holding History

UBS Group’s Portfolio ACUR Stock Details ACUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-31
Closed – – 8235
2016
Q1 		$0 Buy
+31
New +$66 ﹤0.01% 8617
2015
Q3 		– Sell
-1,096
Closed -$5K – 8888
2015
Q2 		$5K Buy
1,096
+767
+233% +$3.19K ﹤0.01% 7916
2015
Q1 		$1K Sell
329
-1,432
-81% -$4.57K ﹤0.01% 8646
2014
Q4 		$4K Buy
+1,761
New +$4.87K ﹤0.01% 9168

Other funds holding ACUR

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.61B AUM 19.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

UBS Group's ACUR Position: Q2 2016 in Review

UBS Group sold out of Acura Pharmaceuticals (ACUR) in Q2 2016, closing a stake of 31 shares.

UBS Group first reported a position in ACUR in Q4 2014 and held it in 4 quarters. The position peaked at $5K in Q2 2015. 22 funds tracked by Wall St. Rank hold ACUR as of Q2 2016.

  • UBS Group reported no remaining Acura Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • UBS Group sold 31 Acura Pharmaceuticals shares in Q2 2016.
  • UBS Group first reported a position in Acura Pharmaceuticals in Q4 2014 and held it in 4 quarters.
  • UBS Group's Acura Pharmaceuticals position peaked at $5K in Q2 2015.
  • 22 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q2 2016.

Based on UBS Group's 13F filing for Q2 2016, filed 12 Aug 2016.